Effects of gastric inhibitory polypeptide, glucagon‐like peptide‐1 and glucagon‐like peptide‐1 receptor agonists on Bone Cell Metabolism

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 122, Iss. 1, 2018-01 ,pp. : 25-37

John Wiley & Sons Inc

Access to resources Recommend Favorite

CARDIAC EFFECTS GLUCAGON‐LIKE PEPTIDE 1 WITH CHITOSAN‐BASED SCAFFOLD AFTER INDUCING MYOCARDIAL INFARCTION IN CANINES

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. S3, 2015-05 ,pp. : 22-22

John Wiley & Sons Inc

Access to resources Recommend Favorite

Localisation of occult extra‐pancreatic insulinoma using glucagon‐like peptide‐1 receptor molecular imaging

By  

INTERNAL MEDICINE JOURNAL, Vol. 48, Iss. 1, 2018-01 ,pp. : 97-98

John Wiley & Sons Inc

Access to resources Recommend Favorite

Overnight hypoxic exposure and glucagon-like peptide-1 and leptin levels in humans

By Snyder Eric M.   Carr Richard D.   Deacon Carolyn F.   Johnson Bruce D.  

Applied Physiology, Nutrition, and Metabolism, Vol. 33, Iss. 5, 2008-10 ,pp. : 929-935

NRC Research Press

Access to resources Recommend Favorite

Xenopus‐derived glucagon‐like peptide‐1 and polyethylene‐glycosylated glucagon‐like peptide‐1 receptor agonists: long‐acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 175, Iss. 3, 2018-02 ,pp. : 544-557

John Wiley & Sons Inc

Access to resources Recommend Favorite